Hans-Peter Gerber - Mar 1, 2025 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Edward C. Albini as attorney-in-fact for Hans-Peter Gerber
Stock symbol
STRO
Transactions as of
Mar 1, 2025
Transactions value $
-$7,347
Form type
4
Date filed
3/4/2025, 06:34 PM
Previous filing
Sep 20, 2024
Next filing
Apr 8, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +11.3K +46.64% $0.00 35.4K Mar 1, 2025 Direct
transaction STRO Common Stock Tax liability -$7.35K -4.62K -13.06% $1.59 30.7K Mar 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Units (RSUs) Options Exercise $0 -11.3K -25% $0.00 33.8K Mar 1, 2025 Common Stock 11.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.